Phase 1 ARB Clinical Trials
16 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–16 of 16 trials
Recruiting
Phase 1
A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation
Advanced Solid Tumors Harboring KRAS G12C Mutation
Bayer104 enrolled10 locationsNCT06659341
Recruiting
Phase 1
A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health
Marburg Virus Disease
International AIDS Vaccine Initiative112 enrolled2 locationsNCT07425821
Recruiting
Phase 1Phase 2
An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
Ornithine Transcarbamylase DeficiencyOrnithine Transcarbamylase Deficiency DiseaseUrea Cycle Disorders, Inborn+1 more
iECURE, Inc.20 enrolled12 locationsNCT06255782
Recruiting
Phase 1Phase 2
Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
ARBBVMDAutosomal-Dominant Bestrophinopathy+1 more
Opus Genetics, Inc10 enrolled4 locationsNCT07185256
Recruiting
Phase 1
A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Avistone Biotechnology Co., Ltd.96 enrolled5 locationsNCT06716138
Recruiting
Phase 1
A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Jiangsu HengRui Medicine Co., Ltd.120 enrolled1 locationNCT07189949
Recruiting
Phase 1Phase 2
A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.
Healthy ParticipantsSarbecovirus
SK Bioscience Co., Ltd.368 enrolled2 locationsNCT07280858
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities
Solid Tumors Harboring NTRK FusionNTRKNTRK Gene Fusion+1 more
Cullgen (Shanghai),Inc42 enrolled6 locationsNCT07394374
Recruiting
Phase 1
A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation
Solid Tumors Harboring a TP53 Y220C Mutation
Changchun GeneScience Pharmaceutical Co., Ltd.82 enrolled1 locationNCT06908434
Recruiting
Phase 1
A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Jiangsu HengRui Medicine Co., Ltd.120 enrolled1 locationNCT07142980
Recruiting
Phase 1Phase 2
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
Platinum Resistant Ovarian CancerPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more
TILT Biotherapeutics Ltd.29 enrolled3 locationsNCT05271318
Recruiting
Phase 1Phase 2
HP Pyruvate MRI in Cancers
ImageTumorsWarburg Effect
University of Maryland, Baltimore25 enrolled1 locationNCT05697406
Recruiting
Phase 1Phase 2
Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
Advanced Solid Tumors Harboring NTRK FusionPrimary Central Nervous System Tumors Harboring NTRK Fusion
Beijing InnoCare Pharma Tech Co., Ltd.70 enrolled1 locationNCT05745623
Recruiting
Phase 1
Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations
Gliomas Harboring IDH1 and/or IDH2 Mutations
Hutchmed52 enrolled1 locationNCT07025018
Recruiting
Phase 1Phase 2
Halting Ornithine Transcarbamylase Deficiency With Recombinant AAV in ChildrEn
Ornithine Transcarbamylase Deficiency
University College, London12 enrolled1 locationNCT05092685
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate extended release tablet against the innovator 5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate extended release tablet conducted under fasting conditions in healthy male and female volunteers
5-O-ethyl 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate is indicated for the treatment of hypertension.
Zenith Technology Corporation Limited32 enrolled1 locationACTRN12622001178730